http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Barlesi, F.,Scherpereel, A.,Gorbunova, V.,Gervais, R.,Vikströ,m, A.,Chouaid, C.,Chella, A.,Kim, J. H.,Ahn, M. J.,Reck, M.,Pazzola, A.,Kim, H. T.,Aerts, J. G,Morando, C.,Loundou, A.,Groen, H. J. M. Oxford University Press 2014 Annals of oncology Vol.25 No.5
<P>The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous non–small cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevacizumab–pemetrexed. At a median follow-up of 14.8 months, OS events occurred in 58% of all patients. OS was numerically longer with bevacizumab–pemetrexed versus bevacizumab when measured from randomization (17.1 versus 13.2 months, HR, 0.87 [0.63–1.21]; P=0.29). Second-line therapy was administered in 77% and 70% of patients in the bevacizumab and bevacizumab–pemetrexed arms, respectively.</P>